Characterisation of availability in the body of the active substance(s) of the newly developed patch Esflurbiprofen Topical System (EFTS) in comparison with a marketed oral flurbiprofen-containing tablet formulation after multiple dose administration including adhesion assessment of the patch - a phase I, open-label, randomised, 2-period, cross-over study in healthy subjects

2024-513058-31-00 Protocol TK-254RX-0102 Human pharmacology (Phase I) - Other Ended

Start 7 Jan 2025 · End 24 Feb 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol TK-254RX-0102

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 26
Countries 1
Sites 1

bioavailability and patch adhesion trial with healthy volunteers, therapeutic indication not studied

Key facts

Sponsor
Teikoku Seiyaku Co. Ltd.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
7 Jan 2025 → 24 Feb 2025
Decision date (initial)
2024-10-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

bioavailability and patch adhesion trial with healthy volunteers, therapeutic indication not studied

VersionLevelCodeTermSystem organ class
20.0 LLT 10002549 Ankle sprain 10022117
20.0 LLT 10028338 Muscle sprains 10022117
20.0 LLT 10028337 Muscle sprain 10022117
20.0 LLT 10002550 Ankle sprains and strains 10022117
21.1 LLT 10028362 Muscular pains 10028395
27.0 LLT 10006502 Bruise 10022117
20.0 LLT 10028361 Muscular pain 10028395

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Teikoku Seiyaku Co. Ltd.

Sponsor organisation
Teikoku Seiyaku Co. Ltd.
Address
567 Sanbonmatsu
City
Higashikagawa
Postcode
769-2695
Country
Japan

Scientific contact point

Organisation
Teikoku Seiyaku Co. Ltd.
Contact name
Director, Regulatory Strategy & Intelligence

Public contact point

Organisation
Teikoku Seiyaku Co. Ltd.
Contact name
Director, Regulatory Strategy & Intelligence

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 26 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
SocraTec R&D Concepts in Drug Research and Development GmbH
CPU, Mainzerhofplatz 14, Erfurt-Altstadt, Erfurt

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-01-07 2025-02-24 2025-01-07 2025-01-20

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-02 Germany Acceptable
2024-10-08
2024-10-09